Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(13):939; doi:10.1093/jnci/95.13.939
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 13, 939, July 2, 2003
© 2003 Oxford University Press

NEWS

In Brief

The first 10% of the full text of this article appears below.

The American Society of Clinical Oncology held its 39th annual meeting last month. More than 3,500 abstracts were included in the meeting. Some highlights are summarized below. The abstracts for the studies are available at http://www.asco.org.

Chemo-Cetuximab Combo Studied in Patients With Metastatic Colorectal Cancer

A new study suggests that the cancer drug cetuximab (Erbitux) in combination with irinotecan more effectively shrinks tumors and delays tumor progression compared with the standard treatment alone.

Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor. Preliminary studies of the . . . [Full Text of this Article]

Gene Expression Profiling May Help Predict Response to Chemotherapy

Statins May Reduce Risk of Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?